Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

S&P Futures Muted in Thin Post-Christmas Trade

March S&P 500 E-Mini futures (ESH26) are trending down -0.03% this morning as trading resumed after the Christmas holiday, with activity subdued and volumes expected to remain light ahead of a shortened New Year’s week.

Higher bond yields today are weighing on S&P 500 futures. The 10-year T-note yield rose two basis points to 4.15%.

Fundamentals

See More
  • Market Capitalization, $K 1,180,283
  • Shares Outstanding, K 105,855
  • Annual Sales, $ 0 K
  • Annual Income, $ -846,420 K
  • EBIT $ -793 M
  • EBITDA $ -785 M
  • 60-Month Beta 1.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 116.62% (-14.75%)
  • Historical Volatility 67.08%
  • IV Percentile 64%
  • IV Rank 17.89%
  • IV High 384.04% on 11/04/25
  • IV Low 58.37% on 01/22/25
  • Expected Move (DTE 19) 2.21 (19.82%)
  • Put/Call Vol Ratio 1.72
  • Today's Volume 16,413
  • Volume Avg (30-Day) 7,185
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 109,338
  • Open Int (30-Day) 144,834
  • Expected Range 8.94 to 13.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.26
  • Number of Estimates 9
  • High Estimate -0.53
  • Low Estimate -1.77
  • Prior Year -1.85
  • Growth Rate Est. (year over year) +31.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.29 +34.50%
on 12/03/25
11.80 -5.50%
on 12/15/25
+1.67 (+17.62%)
since 11/26/25
3-Month
7.48 +49.06%
on 11/11/25
18.57 -39.94%
on 10/30/25
-3.85 (-25.67%)
since 09/26/25
52-Week
7.48 +49.06%
on 11/11/25
44.28 -74.82%
on 02/11/25
-25.27 (-69.38%)
since 12/26/24

Most Recent Stories

More News
S&P Futures Muted in Thin Post-Christmas Trade

March S&P 500 E-Mini futures (ESH26) are trending down -0.03% this morning as trading resumed after the Christmas holiday, with activity subdued and volumes expected to remain light ahead of a shortened...

NVDA : 190.53 (+1.02%)
BHVN : 11.15 (+3.15%)
INTC : 36.20 (+0.11%)
NEM : 105.78 (+1.00%)
MU : 284.79 (-0.66%)
LRCX : 178.07 (+0.42%)
NKE : 60.93 (+1.55%)
DVAX : 15.38 (unch)
CPNG : 24.27 (+6.45%)
FCX : 53.04 (+2.16%)
ESH26 : 6,979.25s (-0.05%)
ON : 54.93 (-0.27%)
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

NEW HAVEN, Conn. , Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...

BHVN : 11.15 (+3.15%)
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

LONDON and NEW HAVEN, Conn. , Dec. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) announced today that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society...

BHVN : 11.15 (+3.15%)
Biohaven Insiders Bet $33 Million on a Turnaround

Biohaven's leadership made a massive multi-million dollar investment in their own stock, signaling deep confidence in the company's turnaround plan.

BHVN : 11.15 (+3.15%)
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

NEW HAVEN, Conn. , Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd.  (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 11.15 (+3.15%)
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

NEW HAVEN, Conn. , Nov. 12, 2025 /PRNewswire/ -- Biohaven Ltd.  (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 11.15 (+3.15%)
Biohaven Announces Proposed Public Offering of Common Shares

NEW HAVEN, Conn. , Nov. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing...

BHVN : 11.15 (+3.15%)
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

NEW HAVEN, Conn. , Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and...

BHVN : 11.15 (+3.15%)
FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

NEW HAVEN, Conn. , Nov. 4, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

BHVN : 11.15 (+3.15%)
BTIG Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

BTIG analyst Thomas Shrader maintained a Buy rating on Biohaven Ltd. yesterday and set a price target of $33.00. The company’s shares closed yesterday at $17.36.Elevate Your Investing Strategy: Take...

BHVN : 11.15 (+3.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut....

See More

Key Turning Points

3rd Resistance Point 13.42
2nd Resistance Point 12.31
1st Resistance Point 11.73
Last Price 11.15
1st Support Level 10.04
2nd Support Level 8.94
3rd Support Level 8.36

See More

52-Week High 44.28
Fibonacci 61.8% 30.22
Fibonacci 50% 25.88
Fibonacci 38.2% 21.54
Last Price 11.15
52-Week Low 7.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar